Cochrane Skin is pleased to announce the publication of the updated version of the living review Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. This new version included 204 randomized clinical trials with 67,889 participants with moderate to severe psoriasis.

Key messages

• The biologics infliximab, xeligekimab, bimekizumab, ixekizumab and risankizumab are the most effective treatments compared with placebo for achieving PASI 90 in people with moderate-to-severe psoriasis, based on high- to moderate-confidence evidence. Bimekizumab ixekizumab, and risankizumab had a better chance of achieving complete or near-complete remission than secukinumab, brodalumab, and guselkumab. 

• There was no significant difference between the treatments and placebo for the risk of serious adverse events, and the safety evidence for most interventions was of low quality.

To find out more, consult the full review in the Cochrane Library.